EMA Headquarters to Move to Amsterdam
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use…
Crucell
Last updated: 13.02.2014
Address: Main building, Archimedesweg 4-6, 2333 CN Leiden,Netherlands
Tel: +31(0) 71 519 91 00
Company description
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge.
Innovation is the drive force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology.
Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel & endemic and respiratory fields. We are the largest independent vaccine company in the world.
Products and services
Our vaccine business provides stable and predictable sales and cash flow. In 2009, we sold more than 115 million vaccine doses in over 100 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel & endemic, and respiratory.
Related
Interview: Leo De Haan – Managing Director Benelux, Aurobindo, The…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in…
The Netherlands: A Fertile Garden for Innovation
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by…
Forging the Future of Healthcare in the Netherlands
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the…
Interview: Karel Fol – Country Manager Benelux, Sobi, The Netherlands
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to…
Interview: Paul Korte – General Manager, Janssen Netherlands
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position…
Interview: Hans Hofstraat – Vice President, Philips Research, The…
In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution,…
Interview: Roland van Esch – Managing Director, Zimmer Biomet, The…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the…
Interview: Hennie Henrichs – General Manager Benelux & Nordics, Teva,…
Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the…
Interview: Aarnoud Overkamp – Managing Director, Takeda Netherlands
Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding…
Interview: Lo Wuite – General Manager Managed Equipment Services Europe;…
In many aspects, 2016 truly marks the dawn of a new era for Toshiba Medical Systems. Lo Wuite (LW), General Manager…
Interview: Fred Westdijk – Vice President Life Sciences & Healthcare;…
DHL Supply Chain Benelux understands the challenges life sciences companies face and has developed solutions to…
